Our Big Idea: An Anti-Infective Silver Bullet

Our mission is to prove our disruptive new "peptoid" anti-infectives destroy humanity's top threat - highly infectious pandemic microbes - like untreatable viruses, drug-resistant bacteria, and drug-resistant fungi. Maxwell's anti-infectives have been shown by multiple independent labs (including Stanford, NYU and others) to be rapid killers of the worst viruses, drug-resistant fungi and treatment-resistant bacteria. These labs show Maxwell peptoids are highly selective for pathogens over human cells, are biostable, effective at low doses, and rapidly destroy biofilm defenses. We are in preclinical stage now, preparing for human trials.

A Treatment for Viral Infections is Possible

Maxwell's disruptive new synthetic peptoid drug class is a functional mimic of Human Cathelicidin Antimicrobial Peptide (CAMP) also known as LL-37. For over 500 million years, LL-37 has successfully defended mammals against viruses without allowing viruses to develop significant resistance. Mimicking LL-37, our peptoids enter the envelope that surrounds the virus, and entangle the nucleic acids of the virus - the equivalent of injecting a sticky glue into the internal gears of a complex machine.

Peptoid Biomimetics Explained

Biomimicry is a proven approach to innovation in therapeutic drug development that simply mimics the natural functions of a healthy body. At Maxwell, we have invented and patented a new drug class we call "antimicrobial peptoids" - functional mimics of the human body's natural antimicrobial peptides, but with added power, allowing our peptoids to fight super bugs longer and harder than any known natural peptide.

Antimicrobial Peptoid

Learn more about antimicrobial peptoids, set to potentially change the way we treat infections.